Ocular Therapeutix is a biotechnology business based in the US. Ocular Therapeutix shares (OCUL) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $8.78 – a decrease of 11.49% over the previous week. Ocular Therapeutix employs 267 staff and has a trailing 12-month revenue of around $61.1 million.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| Latest market close | $8.78 |
|---|---|
| 52-week range | $2.15 - $11.78 |
| 50-day moving average | $9.83 |
| 200-day moving average | $7.98 |
| Wall St. target price | $17.22 |
| PE ratio | N/A |
| Dividend yield | N/A |
| Earnings per share (TTM) | $-1.09 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $8.69 from 2024-11-18
| 1 week (2024-11-13) | -18.02% |
|---|---|
| 1 month (2024-10-18) | -23.30% |
| 3 months (2024-08-20) | -1.70% |
| 6 months (2024-05-20) | 38.16% |
| 1 year (2023-11-20) | 269.79% |
|---|---|
| 2 years (2022-11-18) | 191.61% |
| 3 years (2021-11-19) | 29.90% |
| 5 years (2019-11-20) | 208.70% |
| Revenue TTM | $61.1 million |
|---|---|
| Gross profit TTM | $-6,508,000 |
| Return on assets TTM | -22.37% |
| Return on equity TTM | -72.67% |
| Profit margin | -226.46% |
| Book value | $2.43 |
| Market Capitalization | $1.5 billion |
TTM: trailing 12 months
We're not expecting Ocular Therapeutix to pay a dividend over the next 12 months.
Over the last 12 months, Ocular Therapeutix's shares have ranged in value from as little as $2.145 up to $11.775. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Ocular Therapeutix's is 1.256. This would suggest that Ocular Therapeutix's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Ocular Therapeutix, Inc. , a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is developing AXPAXLI, an axitinib intravitreal implant that is in phase 3 trials for the treatment of wet age-related macular degeneration and other retinal diseases; PAXTRAVA, a travoprost intracameral implant, which is in phase 2 clinical trials for the treatment of open-angle glaucoma or ocular hypertension; OTX-CSI, a cyclosporine intracanalicular insert that has completed phase 2 clinical trials for the treatment of dry eye disease; and OTX-DED, a dexamethasone intracanalicular insert, which is in phase 2 clinical trials for the short-term treatment of the signs and symptoms of dry eye disease. In addition, the company offers modulator for intermediate and late dry age-related macular degeneration; and gene delivery for inherited retinal degenerations and protein biofactory indications. The company has a strategic collaboration with Regeneron Pharmaceuticals, Inc. (Regeneron) for the development and commercialization of products using the company's sustained-release hydrogel in combination with Regeneron's large molecule VEGF-targeting compounds for the treatment of retinal diseases; and AffaMed Therapeutics Limited for the development and commercialization of DEXTENZA and OTX-TIC.
Robinhood Launches Presidential Election Event Contracts Ahead of the Nov 5 Presidential Election
Explore the best bonuses for opening a new brokerage account.
These are the best trading platforms for beginners, according to Finder’s comprehensive analysis.
Compare pros, cons, research tools and reviews for these two trading platforms.
Check out our picks of the best trading apps for beginners, options traders, hands-off investors and more.
See our picks of the best brokerage accounts, including Fidelity, SoFi, Charles Schwab, Public, Robinhood and E*TRADE .
What you need to know about investing in the leading indicator for the overall US stock market.
Maximize $10,000 with broker bonuses, IRA contribution matches, index funds, stocks, ladder CDs, hiring a financial advisor and more.
Top ways to invest $20K include stocks, retirement accounts, conservative investments, ETFs and more. See our full list here.
A deep dive into the highlights and limitations of Robinhood.